ApprovalTrail

Drug · DIN 02470373

RENFLEXIS

SINGLE-USE VIAL

Yes: authorized and sold in Canada

Authorized, and the company reports that it sells it in Canada.

Status Marketed since March 22, 2018; first marketed March 22, 2018.
Drug Identification Number (DIN)
02470373
Company (DIN owner)
Samsung Bioepis Co., LtdIncheon, Incheon, Korea, Republic Of
Schedule
Schedule d; Prescription
Dosage form
Powder For Solution
Route
Intravenous
Therapeutic class (ATC)
Infliximab L04AB02
Class
Human
Record last updated
August 12, 2026

Active ingredients

As listed in the Drug Product Database.

IngredientStrengthPer
INFLIXIMAB100 MGVIAL

Notices of Compliance

Health Canada approvals that name this DIN.